Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 17/20 | 0.71 |
| ▸ | BAK1 | Q16611 | 7/20 | 0.71 |
| ▸ | BCL2L1 | Q07817 | 12/20 | 0.65 |
| ▸ | HTR7 | P34969 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29846744 | 1.00 | BCL2 (0.71) | BCL2BAK1BCL2L1HTR7KDM4E | |
| SCHEMBL1956895 | 0.92 | HTR7 (0.74) | BCL2BAK1BCL2L1HTR7KDM4E | |
| SCHEMBL20778266 | 0.90 | BCL2 (0.70) | BCL2BAK1BCL2L1HTR7KDM4E | |
| SCHEMBL30688260 | 0.90 | BCL2 (0.70) | BCL2BAK1BCL2L1HTR7KDM4E | |
| SCHEMBL29137691 | 0.89 | BCL2 (0.57) | BCL2BAK1BCL2L1HTR7KDM4E | |
| SCHEMBL8214259 | 0.88 | HTR7 (0.62) | BCL2BAK1BCL2L1HTR7 | |
| SCHEMBL15938164 | 0.88 | HTR7 (0.81) | BCL2BAK1BCL2L1HTR7KDM4E | |
| Benzene SCHEMBL27864093 | 0.87 | BCL2 (0.64) | BCL2BAK1BCL2L1HTR7 | |
| SCHEMBL22169036 | 0.87 | BCL2 (0.72) | BCL2BAK1BCL2L1HTR7ALDH1A1 | |
| SCHEMBL19308887 | 0.87 | BCL2 (0.78) | BCL2BAK1BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140923-A1 | Method for Preparing Key Intermediate of ABT-737 and Method for Preparing ABT-737 | XEON BIOPHARMACEUTICAL LIMITED (CN) | 2024-05-02 | — | — | US | claimed |
| WO-2022246929-A1 | PREPARATION METHOD FOR ABT-737 KEY INTERMEDIATE AND PREPARATION METHOD FOR ABT-737 | 苏州正永生物医药有限公司 | 2022-12-01 | — | — | WO | claimed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240140923-A1 | Method for Preparing Key Intermediate of ABT-737 and Method for Preparing ABT-737 | XEON BIOPHARMACEUTICAL LIMITED (CN) | 2024-05-02 | — | — | US | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022246929-A1 | PREPARATION METHOD FOR ABT-737 KEY INTERMEDIATE AND PREPARATION METHOD FOR ABT-737 | 苏州正永生物医药有限公司 | 2022-12-01 | — | — | WO | disclosed |
| EP-3788052-A1 | ACYL PHOSPHONAMIDATES AND ACYL BENZYLAMINES THAT ARE BCL FAMILY ANTAGONISTS FOR USE IN CLINICAL MANAGEMENT OF CONDITIONS CAUSED OR MEDIATED BY SENESCENT CELLS AND FOR TREATING CANCER | Unity Biotechnology, Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10703745-B2 | Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703745-B2 | Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | UNITY BIOTECHNOLOGY, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080194691-A1 | Apoptosis Promoters | ABBOTT LABORATORIES (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1888543-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127364-A1 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194691-A1 | Apoptosis Promoters | BAX, BCL2, BCOR | BCL2 2/4885BAK1 17/4885BCL2L1 6/4885 |
| US-10703745-B2 | Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | BAX, BCL2, BCOR | BCL2 2/4885BAK1 37/4885BCL2L1 17/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | BCL2 59/4885BAK1 324/4885BCL2L1 358/4885 |
| US-20240140923-A1 | Method for Preparing Key Intermediate of ABT-737 and Method for Preparing ABT-737 | BAX, BCL2, CASP7 | BCL2 2/4885BAK1 25/4885BCL2L1 22/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | BCL2 4/4885BAK1 7/4885BCL2L1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.